Home > Riviste > Minerva Anestesiologica > Fascicoli precedenti > Minerva Anestesiologica 2021 February;87(2) > Minerva Anestesiologica 2021 February;87(2):230-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

EXPERTS’ OPINION   Free accessfree

Minerva Anestesiologica 2021 February;87(2):230-7

DOI: 10.23736/S0375-9393.20.14515-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Opioid free anesthesia: evidence for short and long-term outcome

Dario BUGADA 1 , Luca F. LORINI 1, Patricia LAVAND’HOMME 2

1 Department of Emergency and Intensive Care, ASST Papa Giovanni XXIII, Bergamo, Italy; 2 Saint-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium



The introduction of synthetic opioids in clinical practice played a major role in the history of anesthesiology. For years, anesthesiologists have been thinking that opioids are needed for intraoperative anesthesia. However, we now know that opioids (especially synthetic short-acting molecules) are definitely not ideal analgesics and may even be counterproductive, increasing postoperative pain. As well, opioids have revealed important drawbacks associated to poor perioperative outcomes. As a matter of fact, efforts in postoperative pain management in the last 30 years were driven by the idea of reducing/eliminating opioids from the postoperative period. However, a modern concept of anesthesia should eliminate opioids already intra-operatively towards a balanced, opioid-free approach (opioid-free anesthesia - OFA). In OFA drugs and techniques historically proven for their efficacy are combined in rational and defined protocols. They include ketamine, alpha-2 agonists, lidocaine, magnesium, anti-inflammatory drugs and regional anesthesia. Promising results have been obtained on perioperative outcome. For sure, analgesia is not reduced with OFA, but it is effective and with less opioid-related side effects. These benefits may be of particular importance in some high-risk patients, like OSAS, obese and chronic opioid-users/abusers. OFA may also increase patient-reported outcomes; despite it is difficult to specifically rule out the effect of intraoperative opioids. Finally, few data are available on long-term outcomes (persistent pain and opioid abuse, cancer outcome). New studies and data are required to elaborate the optimal approach for each patient/surgery, but interest and publication are increasing and may open the road to the wider adoption of OFA.


KEY WORDS: Analgesics, opioid; Adjuvants, pharmaceutic; Anesthesia

inizio pagina